LP250846-5
Vedolizumab Ab
Active
Description
In clinical trials, antibodies to vedolizumab (ATV) were present in about 4% of patients at any given time and were persistent in only 1% or less of patients receiving vedolizumab. https://www.healthcare.uiowa.edu/path_handbook/handbook/test3424.html In those patients with anti-vedolizumab antibodies, vedolizumab clearance was increased by about 12%, and for those with persistent antibodies, the trough concentration of vedolizumab was below detectable limits. Anti-drug antibodies can be one cause of treatment failure for vedolizumab as well as other monoclonal antibody therapeutics. PMID: 25996351 Source: Regenstrief LOINC
Basic Part Properties
- Part Name
- Vedolizumab Ab
- Part Display Name
- Vedolizumab Ab
- Part Type
- Component (Describes the core component or analyte measured)
- Created On
- 2017-05-09
- Construct for LOINC Short Name
- Vedolizumab Ab
LOINC Terminology Service (API) using HL7® FHIR® Get Info
Requests to this service require a free LOINC username and password. Below is a sample of the possible capabilities. See the LOINC Terminology Service documentation for more information.
Language Variants Get Info
| Tag | Language | Translation |
|---|---|---|
| fr-FR | French (France) | Védolizumab anticorps |
LOINC Copyright
Copyright © Regenstrief Institute, Inc. All Rights Reserved. To the extent included herein, the LOINC table and LOINC codes are copyright © Regenstrief Institute, Inc. and the Logical Observation Identifiers Names and Codes (LOINC) Committee. See https://